Reference : Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/24080
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid
English
Wood, J. [> > > >]
Bonjean, K. [> > > >]
Ruetz, S. [> > > >]
Bellahcene, Akeila mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases >]
Devy, L. [> > > >]
Foidart, Jean-Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Gynécologie - Obstétrique >]
Castronovo, Vincenzo mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire >]
Green, J. R. [> > > >]
Sep-2002
Journal of Pharmacology and Experimental Therapeutics
Amer Soc Pharmacology Experimental Therapeutics
302
3
1055-1061
Yes (verified by ORBi)
International
0022-3565
Bethesda
[en] Bisphosphonates ; Zoledronic acid ; Angiogenesis
[en] Bisphosphonate drugs inhibit osteoclastic bone resorption and are widely used to treat skeletal complications in patients with tumor-induced osteolysis. We now show that zoledronic acid, a new generation bisphosphonate with a heterocyclic imidazole substituent, is also a potent inhibitor of angiogenesis. In vitro, zoledronic acid inhibits proliferation of human endothelial cells stimulated with fetal calf serum, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (IC50 values 4.1, 4.2, and 6.9 muM, respectively), and modulates endothelial cell adhesion and migration. In cultured aortic rings and in the chicken egg chorioallantoic membrane assay, zoledronic acid reduces vessel sprouting. When administered systemically to mice, zoledronic acid potently inhibits the angiogenesis induced by subcutaneous implants impregnated with bFGF [ED50, 3 mug/kg (7.5 nmol/kg) s.c.]. These findings indicate that zoledronic acid has marked antiangiogenic properties that could augment its efficacy in the treatment of malignant bone disease and extend its potential clinical use to other diseases with an angiogenic component.
Novartis
http://hdl.handle.net/2268/24080

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
WOOD J Pharmacol 2002.pdfNo commentaryPublisher postprint336.92 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.